IL-4 drives exhaustion of CD8 ⁺ CART cells.

Autor: Stewart CM; T Cell Engineering, Mayo Clinic, Rochester, MN, USA.; Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, MN, USA.; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA., Siegler EL; T Cell Engineering, Mayo Clinic, Rochester, MN, USA.; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Sakemura RL; T Cell Engineering, Mayo Clinic, Rochester, MN, USA.; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Cox MJ; T Cell Engineering, Mayo Clinic, Rochester, MN, USA., Huynh T; T Cell Engineering, Mayo Clinic, Rochester, MN, USA.; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Kimball B; T Cell Engineering, Mayo Clinic, Rochester, MN, USA.; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Mai L; T Cell Engineering, Mayo Clinic, Rochester, MN, USA.; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Can I; T Cell Engineering, Mayo Clinic, Rochester, MN, USA.; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Manriquez Roman C; T Cell Engineering, Mayo Clinic, Rochester, MN, USA., Yun K; T Cell Engineering, Mayo Clinic, Rochester, MN, USA.; Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, MN, USA.; Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA., Sirpilla O; T Cell Engineering, Mayo Clinic, Rochester, MN, USA.; Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, MN, USA.; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA., Girsch JH; T Cell Engineering, Mayo Clinic, Rochester, MN, USA.; Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, MN, USA.; Department of Molecular Medicine, Mayo Clinic, Rochester, MN, USA., Ogbodo E; T Cell Engineering, Mayo Clinic, Rochester, MN, USA.; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Mohammed Ismail W; Department of Lab Medicine and Pathology, Mayo Clinic, Rochester, MN, USA., Gaspar-Maia A; Department of Lab Medicine and Pathology, Mayo Clinic, Rochester, MN, USA., Budka J; Department of Oncology, Gilead Sciences Inc., Foster City, CA, USA., Kim J; Department of Oncology, Gilead Sciences Inc., Foster City, CA, USA., Scholler N; Department of Oncology, Gilead Sciences Inc., Foster City, CA, USA., Mattie M; Department of Oncology, Gilead Sciences Inc., Foster City, CA, USA., Filosto S; Department of Oncology, Gilead Sciences Inc., Foster City, CA, USA., Kenderian SS; T Cell Engineering, Mayo Clinic, Rochester, MN, USA. kenderian.saad@mayo.edu.; Division of Hematology, Mayo Clinic, Rochester, MN, USA. kenderian.saad@mayo.edu.; Department of Immunology, Mayo Clinic, Rochester, MN, USA. kenderian.saad@mayo.edu.

Publikováno v: Nature communications [Nat Commun] 2024 Sep 12; Vol. 15 (1), pp. 7921. Date of Electronic Publication: 2024 Sep 12.

Metalloenzymes

Autor: Pollard, J. W., Danilkovitch-Miagkova, A., Minaguchi, T., Waite, K. A., Buys, T. P. H., Lam, W. L., Müller-Hermelink, H. K., Ott, G., Robb, V. A., Henske, E. P., Lynge, E., Boyd, N., Geisler, C., Seger, R., De Wolf-Peeters, C., Sagaert, X., Sheng, S., Ribatti, D., Verstovsek, S., Akin, C., Stack, M. S., Kitada, S., Gartenhaus, R., Moretti, F., Frühwald, Michael C., Mooi, W. J., Krausz, T., Kefford, R., Peikert, T., Specks, U., Tueting, T., Pföhler, C., Blask, D. E., Stevens, R. G., Nies, A. T., Gotoh, N., Tsuchida, N., Escriba, P., Singh, V., Hickey, M., Saunders, C., Xiao, G.-H., Testa, J. R., Furtwängler, R., Scholler, N., Carbone, M., Furge, K., Woude, G. F. V., Roland, W. C., Muschel, R., Hunter, K., Welch, D. R., Vaidya, K. S., Hurst, D. R., Silveira, A. C., Zang, X. A., Bari, R., Silveira, A., Szmulewitz, R., Taylor, J., Rinker-Schaffer, C., Shim, H., Plass, C., Lindsey, J. C., Clifford, S. C., Holdenrieder, S., Steinle, A., Salih, H., Brown, D. A., Breit, S. N., Bauskin, A. R., Mousses, S., Lung, M. L., Alix-Panabieres, C., Pantel, K., Djuzenova, C. S., Dalmay, T., Ahlquist, T., Lothe, R. A., Bhat, K., Setaluri, V., Rutka, J. T., Salhia, B., Cockell, K. A., Radich, J. P., Yamagishi, S.-I., Bignami, M., Verma, M., Kumar, D., Brenner, C., Zhang, Y.-W., Jamieson, D., Chi, Y.-H., Jeang, K.-T., Roninson, I., Dragani, T., Sobolev, A. S., Powers, M. V., Workmann, P., Evans, M. F., Cooper, K., Kausch, I., Doehn, C., Janz, S., Huang, C.-L., Toland, A. E., Osinaga, E., Kaye, F., Lemos, M. C., Thakker, R. V., Teh, B. T., Ponder, B. A. J., Mulligan, L. M., Gullo, C., Klein, G., Wu, X., Araten, D. J., Loeb, L. A., Cheadle, J. P., Lipsick, J., Albihn, A., Henriksson, M., Kremens, B., Germing, U., Zangemeister-Wittke, U., Simon, H.-U., Yu, Y. P., Luo, J., Aman, P.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3341::55b495166b87b688a540ba7f82176c5e
https://opus.bibliothek.uni-augsburg.de/opus4/frontdoor/index/index/docId/73474

Discovery of a novel genomic alteration that renders leukemic cells resistant to CD19-targeted immunotherapies.

Autor: Ghobadi A; Division of Oncology, Washington University School of Medicine, St Louis, MO., Landmann JH; Division of Oncology, Washington University School of Medicine, St Louis, MO., Carter A; Division of Oncology, Washington University School of Medicine, St Louis, MO., Cooper ML; Division of Oncology, Washington University School of Medicine, St Louis, MO., Selli ME; Division of Oncology, Washington University School of Medicine, St Louis, MO., Chang J; Division of Oncology, Washington University School of Medicine, St Louis, MO., Baker M; The University of Texas Health Science Center at Houston, Houston, TX.; Department of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, TX., Miller CA; Division of Oncology, Washington University School of Medicine, St Louis, MO., Ferraro F; Division of Oncology, Washington University School of Medicine, St Louis, MO., Chen DY; Division of Oncology, Washington University School of Medicine, St Louis, MO., Smith AM; Division of Oncology, Washington University School of Medicine, St Louis, MO., LaValle TA; Division of Oncology, Washington University School of Medicine, St Louis, MO., Duncavage EJ; Division of Oncology, Washington University School of Medicine, St Louis, MO., Chou J; Kite, a Gilead Company, Santa Monica, CA., Tam V; Kite, a Gilead Company, Santa Monica, CA., Benoun JM; Kite, a Gilead Company, Santa Monica, CA., Nater J; Kite, a Gilead Company, Santa Monica, CA., Scholler N; Kite, a Gilead Company, Santa Monica, CA., Milletti F; Kite, a Gilead Company, Santa Monica, CA., Vezan R; Kite, a Gilead Company, Santa Monica, CA., Bot A; Kite, a Gilead Company, Santa Monica, CA., Rossi JM; Kite, a Gilead Company, Santa Monica, CA., Singh N; Division of Oncology, Washington University School of Medicine, St Louis, MO.

Publikováno v: Blood advances [Blood Adv] 2022 Oct 25; Vol. 6 (20), pp. 5634-5640.

Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma.

Autor: Scholler N; Kite, a Gilead company, Santa Monica, CA, USA.; Gilead Sciences, Foster City, CA, USA., Perbost R; Veracyte SAS, Marseille, France., Locke FL; Moffitt Cancer Center, Tampa, FL, USA., Jain MD; Moffitt Cancer Center, Tampa, FL, USA., Turcan S; Veracyte SAS, Marseille, France., Danan C; Veracyte SAS, Marseille, France., Chang EC; Kite, a Gilead company, Santa Monica, CA, USA., Neelapu SS; The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Miklos DB; Stanford University School of Medicine, Stanford, CA, USA., Jacobson CA; Dana-Farber Cancer Institute, Boston, MA, USA., Lekakis LJ; University of Miami Health System, Sylvester Comprehensive Cancer Center, Miami, FL, USA., Lin Y; Mayo Clinic, Rochester, MN, USA., Ghobadi A; Washington University School of Medicine, St. Louis, MO, USA., Kim JJ; Kite, a Gilead company, Santa Monica, CA, USA., Chou J; Kite, a Gilead company, Santa Monica, CA, USA., Plaks V; Kite, a Gilead company, Santa Monica, CA, USA., Wang Z; Kite, a Gilead company, Santa Monica, CA, USA., Xue A; Kite, a Gilead company, Santa Monica, CA, USA., Mattie M; Kite, a Gilead company, Santa Monica, CA, USA., Rossi JM; Kite, a Gilead company, Santa Monica, CA, USA., Bot A; Kite, a Gilead company, Santa Monica, CA, USA.; Capstan Therapeutics, San Diego, CA, USA., Galon J; Veracyte SAS, Marseille, France. jerome.galon@crc.jussieu.fr.; INSERM, Sorbonne Université, Université Paris Cité, Centre de Recherche des Cordeliers, Equipe Labellisée Ligue Contre le Cancer, Laboratory of Integrative Cancer Immunology, Paris, France. jerome.galon@crc.jussieu.fr.

Publikováno v: Nature medicine [Nat Med] 2022 Sep; Vol. 28 (9), pp. 1872-1882. Date of Electronic Publication: 2022 Aug 29.

Recent Advances in Artificial Intelligence to Improve Immunotherapy and the Use of Digital Twins to Identify Prognosis of Patients with Solid Tumors.

Autor: D'Orsi, Laura¹ (AUTHOR) laura.dorsi@biomatematica.it, Capasso, Biagio² (AUTHOR) biagio.capasso@marina.difesa.it, Lamacchia, Giuseppe³ (AUTHOR) giuseppe.lamacchia@reginaapostolorum.it, Pizzichini, Paolo⁴ (AUTHOR) pizzichinipaolo@gmail.com, Ferranti, Sergio² (AUTHOR) sergio.ferranti@esercito.difesa.it, Liverani, Andrea³ (AUTHOR) andrea.liverani@reginaapostolorum.it, Fontana, Costantino⁴ (AUTHOR) costantino.fontana@esercito.difesa.it, Panunzi, Simona¹ (AUTHOR) simona.panunzi@biomatematica.it, De Gaetano, Andrea^1,5,6 (AUTHOR) andrea.degaetano@irib.cnr.it, Lo Presti, Elena⁵ (AUTHOR) elena.lopresti@cnr.it

Publikováno v: International Journal of Molecular Sciences. Nov2024, Vol. 25 Issue 21, p11588. 19p.